Limula’s solution team completed a fully automated, 7-day end-to-end CAR T-cell therapy production; from cell input to finished product. The Biopôle-based start-up has now established a growing pipeline of customers committed to using its solution towards clinical use.
To mark the transition from a research oriented organisation to a commercial entity, and to solidify the customer traction built over the past months, the Board decided to reshuffle the founding team and management priorities. The Board of Directors of Limula announces a change at the helm, with Luc Henry to relinquish the title of CEO, and former CFO Thomas Eaton to step into the role to consolidate the company processes for robust execution.
Before joining Limula as CFO and co-founder in 2021, Thomas Eaton worked in management positions at Swiss Re and UBS and as a consultant at Deloitte. He has extensive experience in project management, budget tracking, outsourcing and supplier oversight. Thomas graduated from the University of Basel with a PhD in Material Sciences and holds a Master’s degree in Chemistry from the University of Oxford.
